BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

ProNAi Therapeutics, Inc. 

4717 Campus Drive
Suite 1100
Kalamazoo  Michigan  49008  U.S.A.
Phone: 269-372-3289 Fax: 269-544-1079


SEARCH JOBS










 Company News
ProNAi Therapeutics, Inc. Names New President And Chief Executive Officer 9/3/2014 9:03:12 AM
ProNAi Therapeutics, Inc. Banks $59.5 Million Series D To Fund Non-Hodgkin's Lymphoma Studies 4/21/2014 4:22:07 PM
ProNAi Therapeutics, Inc. Secures $12 Million Series C Financing To Expand Phase II Cancer Studies For PNT2258, A Novel BCL2 Inhibitor, In Defined Lymphoma Patients 1/13/2014 8:17:05 AM
ProNAi Therapeutics, Inc. Reports Anti-Tumor Activity From Ongoing Phase II Clinical Study Of PNT2258, A Novel BCL2-Inhibitor, At American Society of Hematology Annual Meeting 12/10/2013 7:03:32 AM
ProNAi Therapeutics, Inc. to Present Phase II Clinical Data at American Society of Hematology for PNT2258, a BCL2 Targeted Drug 11/8/2013 7:52:07 AM
Marina Biotech, Inc. Announces That Licensee ProNAi Therapeutics, Inc. Reported Phase 1 Study Results Using SMARTICLES® Nucleic Acid Delivery Technology 12/5/2012 9:42:39 AM
ProNAi Therapeutics, Inc. Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting 11/12/2012 8:52:08 AM
Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) and ProNAi Therapeutics, Inc. Announce License Agreement for Up to $14 Million 3/14/2012 6:52:23 AM
ProNAi Therapeutics, Inc. Cleared to Begin Phase I Clinical Trials for the First DNA Interference (DNAi(R)) Therapeutic 3/20/2008 6:20:13 AM
ProNAi Therapeutics, Inc. Announces First DNAi(R) Mechanism of Action Studies for PNT2258 Oncology Drug Candidate 8/23/2007 9:07:05 AM
12